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Abstract: The humanized antibody efalizumab is currently the only T-cell directed biologic 
approved for the treatment of moderate-to-severe psoriasis by both American and European 
authorities. Binding to and blocking the function of the adhesion molecule leukocyte function 
associated antigen 1 (LFA-1), it is believed to interfere with T-cell activation in the lymph 
node, migration through the circulation into the skin, and re-activation in-loco, all of these 
representing central steps in the pathogenesis of psoriasis. A comprehensive clinical develop-
ment program provided large and consistent evidence that efalizumab induces a major clinical 
beneﬁ  t in psoriasis. Efalizumab rapidly and substantially improves psoriatic skin symptoms 
and leads to profound gain in quality of life. It allows safe and effective long-term control of 
psoriasis. Therefore, evidence-based treatment guidelines recommend its use in moderate to 
severe plaque-type psoriasis.
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Clinical aspects of psoriasis
Psoriasis is one of the most common dermatological diseases. Although there is a great 
variation in the prevalence of psoriasis in different countries due to environmental and 
genetic factors, it can be said that it affects roughly 2%–3% of the world’s Caucasian 
population. About 20%–25% of these people suffer from joint involvement (psoriatic 
arthritis).
The disease usually occurs as so-called plaque-type psoriasis, accounting for more 
than 80% of the cases. Clinical features include sharply demarginated, erythematous 
plaques with non-adherent, silvery scales. Pain, itching, and cracking of the skin may 
be prominent as well. These lesions most typically affect elbows, knees, scalp, lumbar, 
and umbilical areas. Guttate psoriasis is often a form that begins in childhood or early 
adulthood; it appears as eruption of scattered 1.0–10 mm “drop” shaped, erythematous, 
scaly papules. Inverse psoriasis is typically localized to the axilla, submammary folds, 
genitocrural area, and neck. These lesions usually have no scale and appear as well-
demarcated, salmon red plaques that can ﬁ  ssure. Palmoplantar psoriasis affects the 
palms and soles, presenting as discrete, erythematous, scaling patches and plaques. 
These lesions are usually bilateral, and involvement of the palms typically stops at the 
wrist-palm junction. The potential of psoriasis to principally affect every site of the 
body is reﬂ  ected by the so-called erythrodermic psoriasis, presenting as generalized 
indurated erythema with diffuse exfoliation of ﬁ  ne scales. The patients may also present 
with fever, chills, rigors, arthralgias, and trouble maintaining core body temperature. 
More rarely, pustular types of psoriasis may occur. Additionally, scalp and nails may 
also be affected. Finally, some 20%–30% of patients develop joint involvement.
Unmet needs in the treatment of psoriasis
Although a wide spectrum of anti-psoriatic therapies is currently available, their 
application is often limited by numerous factors, including insufﬁ  cient practicabil-
ity (topical and phototherapies) and lack of long-term safety (photo- and systemic Biologics: Targets & Therapy 2007:1(3) 302
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therapies); some are either not sufﬁ  ciently effective as a 
monotherapy (retinoids) or are frequently not tolerated 
(fumarates). These shortcomings of established anti-psoriatic 
therapies are reﬂ  ected in part by poor satisfaction among 
patients: In a recent survey, only some 25% stated they were 
satisﬁ  ed with the treatment successes encountered (Stern 
et al 2004). Besides, non-compliance is high among psoriatic 
patients (Richards et al 1999). Reasons for dissatisfaction 
and/or non-compliance comprise poor tolerability and/or 
efﬁ  cacy, impracticability, and lack of information on adverse 
drug reactions.
The impact of psoriasis on physical and mental aspects 
of life is still widely underestimated, even though numerous 
studies have documented a high burden of disease compa-
rable to major other entities such as cancer or rheumatoid 
arthritis (Rapp et al 1999). Consequently, improvement of 
health-related quality of life is an integral part of managing 
psoriasis.
Biologics, deﬁ  ned as molecular species generated in cell-
based systems, have the potential to meet some of the above-
mentioned needs (Sterry et al 2004). Major trials evaluating 
biologics in psoriasis have focused on moderate-to-severe 
plaque-type psoriasis. Measures currently used to document 
therapeutic efﬁ  cacy include determination of the affected 
body surface area (BSA), Psoriasis Area and Severity Index 
(PASI), and the Dermatology Life Quality Index (DLQI) 
(Strober et al 2006). In the absence of a precise deﬁ  nition, 
moderate to severe psoriasis is considered to be character-
ised by scores >10 in any of these instruments (Boehncke 
et al 2006a). Treatment success is deﬁ  ned by reduction of 
the respective scores. Typically, the percentage of patients 
achieving at least a 75% reduction in the PASI (PASI-75) is 
considered a good clinical response.
Currently, four biologics are approved for the treatment 
of plaque-type psoriasis (Boehncke et al 2006b). Whereas 
alefacept (approved only by the FDA) and efalizumab both 
interfere with T-cell function, inﬂ  iximab and etanercept block 
the pro-inﬂ  ammatory cytokine TNF-α; the latter three are 
approved by the US Food and Drug Administration (FDA) as 
well as the European Medicines Agency (EMEA). Both agen-
cies are expected to approve the use of adalimumab, another 
TNF-α blocker, in the near future. All biologics mentioned 
have proven safety and efﬁ  cacy as well as practicability and 
improvement of quality of life in double-blind, placebo-
controlled, randomized trials.
Subsequently, the rationale for developing efalizumab, its 
chemistry and pharmacology as well as efﬁ  cacy and safety 
will be discussed in detail.
The role of T -cells in the 
pathogenesis of psoriasis
There is agreement today that immunological mechanisms 
play an important role in the pathogenesis of many chronic 
relapsing inﬂ  ammatory skin diseases, such as psoriasis 
(Krueger 2002; Schön and Boehncke 2005). Evidence of the 
pivotal role played by T-cells in the pathology of psoriasis 
is accumulating, such as
•  presence of activated T-cells in psoriatic lesions (Bjerke 
et al 1978)
•  the ability of activated T-cells to induce the altered 
keratinocyte growth and differentiation pattern typical of 
psoriasis, as demonstrated in the so-called psoriasis SCID 
mouse model: Injection of autologous immunoctyes into 
non-lesional skin grafts from psoriatic donors onto mice 
with a severe combined immune deﬁ  ciency results in 
the phenotype of lesional psoriatic skin (Nickoloff and 
Wrone-Smith 1999)
• efﬁ  cacy of T-cell-targeted immune suppressive drugs, 
such as cyclosporine, and antibodies against the CD25 
receptor and CD4 (Schön and Boehncke 2005)
•  transfer of psoriasis in the process of bone marrow trans-
plantation from a donor suffering from the disease to a 
healthy recipient (Gardembas-Pain et al 1991). Also, pso-
riasis can be “cured” when bone marrow is transplanted 
from a healthy donor to a person with psoriasis (Eedy 
et al 1990).
According to a widely accepted working hypothesis on 
the pathogenesis of psoriasis, antigen-presenting dendritic 
cells of the epidermis transport yet unknown antigens to 
regional lymph nodes and present them to naïve T-cells. 
These respond by activation, proliferation, and maturation 
into effector T-cells, which patrol the body and leave circula-
tion at the site of antigen contact. Subsequently, these cells 
migrate toward the epidermis and upon re-activation, release 
effector molecules, namely pro-inﬂ  ammatory cytokines, 
which in turn contribute substantially to the development 
of the clinically apparent erythemato-squamous plaques 
(Figure 1).
The role of leukocyte function 
associated antigen 1 (LFA-1) 
in the pathogenesis of psoriasis
LFA-1, Mac-1, and p159,95, members of the β2 integrin 
family, are heterodimeric molecules consisting of a β-subunit 
(CD18), common to all three molecules, which is non-
covalently linked to the respective a-chain CD11a (LFA-1), Biologics: Targets & Therapy 2007:1(3) 303
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CD11b (Mac-1), and CD11c (p159,95). T-cells mainly 
express LFA-1 (CD11a/CD18), which is essential for every 
step in the process of immune surveillance and mounting an 
immune response (Dustin et al 2004), namely ﬁ  rm adher-
ence to the wall of blood vessels under blood ﬂ  ow, scanning 
by T cells of other cells within tissues, and formation of 
the immunological synapse between T-cells and antigen-
presenting cells. The ligands for LFA-1 are intercellular adhe-
sion molecules (ICAM). They include ICAM-1, expressed 
on leucocytes, vascular endothelium cells and epithelial 
cells, including keratinocytes, ICAM-2 expressed on resting 
endothelium and lymphocytes and ICAM-3, expressed on 
monocytes and resting lymphocytes.
Thus, LFA-1 is likely to be involved in numerous crucial 
steps of the pathogenesis of psoriasis, namely activation of 
T-cells in lymph nodes upon encounter of antigen transported 
there by dendritic cells of the epidermis, extravazation of 
circulating T-cells in inﬂ  ammatory skin, T-cell re-activation 
in the skin by antigen-presenting cells, and keratinocyte 
interaction with inﬁ  ltrating activated T-cells. Therefore, 
a function-blocking anti LFA-1 antibody should exhibit 
anti-psoriatic efﬁ  cacy based on interference at these points 
(Figure 1).
Development and characterization 
of efalizumab
Efalizumab (Raptiva®, rhuMAb CD11a, hu1124, Genentech, 
Inc., South San Francisco, CA, USA) is a full-length, IgG1 
kappa isotype antibody composed of two identical kappa 
light chains consisting of 214 amino acid residues, and two 
gamma heavy chains consisting of 451 residues. Each light 
chain is covalently coupled through a disulﬁ  de link to a 
heavy chain. The two heavy chains are covalently coupled 
to each other via inter-chain disulﬁ  de bonds consistent with 
the structure of human IgG1. The molecular weight of intact 
efalizumab is 148,841 Da.
Originally developed as a murine anti-CD11a mono-
clonal antibody (MHM24; Hildreth and August 1985), 
efalizumab has been prepared by substituting human DNA 
sequences using genetic engineering methods to reduce 
Figure 1 Mode of action of efalizumab in psoriasis: According to a widely accepted working hypothesis, antigen-presenting dendritic cells of the epider-
mis transport yet unknown antigens to regional lymph nodes and present them to naïve T-cells. These respond by activation, proliferation, and matura-
tion into effector T-cells, which patrol the body and leave circulation at the site of antigen contact. Subsequently, these cells migrate toward the epidermis 
and upon re-activation, release effector molecules, namely pro-inflammatory cytokines. Efalizumab interferes with this process at the LFA-1 dependent 
stages, namely activation of T-cells in lymph nodes (A), extravazation of circulating T-cells in inflammatory skin (B), and T-cell re-activation in the skin (C).
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immunogenicity. In detail, complementarity determining 
regions (CDR) from the murine antibody MHM24 were 
grafted into consensus human IgG1χ heavy and light chain 
sequences. This results in a “humanized” mAb (HuIgG1) in 
which the complementarity-determining regions (CDRs) of 
the murine antibody – important for speciﬁ  c antigen recogni-
tion – are preserved.
Previous studies on murine MHM24 have shown that, 
similar to other anti-CD11a antibodies, it is able to inhibit 
T-cell function.
The consensus sequences for the human heavy chain 
subgroup III (VH-CH1) and the light chain subgroup k 1 were 
used as the framework for the humanization. Several human-
ized variants were made and screened for binding as Fabs. 
To construct the ﬁ  rst Fab variant of humanized MHM24, all 
six CDR residues were transferred from the murine antibody 
to the human framework.
Further variants were constructed by targeted exchange 
of either framework residues, or residues within CDRs using 
the ﬁ  rst variant (Fab-1), as a template. For that purpose, both 
light and heavy chains were completely sequenced for each 
variant. Plasmids containing the sequences were then trans-
formed to Escherichia coli for protein expression.
All variants were tested for CD11a binding in the Jurkat 
cell assay. VL and VH domains of the variant with optimal 
binding characteristics were then transferred to human IgG1 
constant domains, giving the full-length intact humanized 
antibody (Werther et al 1996).
Several in vitro assays were performed to compare 
efalizumab with its parent murine antibody MHM24, includ-
ing the keratinocyte cell-adhesion assay and the mixed 
lymphocyte response assay (MLR).
The results showed that, in these assays, efalizumab 
worked as well as MHM24. In addition, the apparent Kd 
values, as determined by saturation binding using peripheral 
blood mononuclear cells (PBMCs) of two human donors, 
were similar for both MHM24 and efalizumab (0.16 ± 0.01 
nM and 0.13 ± 0.02 nM vs 0.11 ± 0.08 nM and 0.18 ± 0.03 
nM, respectively).
Pharmacodynamics
The pharmacodynamic properties of efalizumab were inves-
tigated in several phase I and phase II studies following 
intravenous and subcutaneous administration, either as a 
single dose or repeated weekly administration.
In the single-dose intravenous study, doses of 0.03–
10 mg/kg were given (Gottlieb et al 2000). Within 24 hours, 
treatment with efalizumab reduced the level of CD11a 
expression on T-cells to 25% of pretreatment levels. This 
suppression persisted as long as efalizumab was present in the 
circulation. In the above mentioned study (iv, single dose), 
CD11a expression returned to baseline within 7–10 days fol-
lowing clearance of efalizumab, without showing any signs 
of lymphocyte depletion. Total white blood cell (WBC) count 
was slightly increased within about 8 hours of efalizumab 
administration; circulating lymphocyte counts were increased 
by day 7. Following multiple weekly dosing, lymphocytes 
remained elevated but returned to baseline after efalizumab 
clearance. This elevation of lymphocyte count is probably 
due to demargination – blocked entry of efalizumab-bound 
cells to tissues.
To achieve the full pharmacodynamic effect, intrave-
nous doses of above 0.3 mg/kg were necessary. Complete 
saturation and maintenance of CD11a binding site down-
regulation on lymphocytes required weekly intravenous 
doses of 0.6 mg/kg, which corresponds to an efalizumab 
plasma concentration of 5 μg/mL.
Several histological changes were observed in psoriatic 
plaques following efalizumab administration. A marked 
reduction of keratin-16, corresponding to decreased disease 
activity, was noted. Keratinocyte ICAM-1 levels were also 
reduced, indicating reduced cytokine-mediated inﬂ  ammation. 
Furthermore, a signiﬁ  cant thinning of the epidermis and 
restoration of normal skin was observed after 28 days of 
treatment, in concordance with reductions of over 50% in 
cutaneous T-cell inﬁ  ltration and reduced CD11a availability 
(Gottlieb et al 2002). These data demonstrate that by reducing 
CD11a on the surface of circulating and cutaneous T-cells, 
efalizumab is able to reverse both the histological signs of 
inﬂ  ammation and the pathological hyperplasia characteristic 
of plaque psoriasis.
In general, the effects of subcutaneous efalizumab on 
lymphocytes were comparable to those observed after 
intravenous dosing. Subcutaneous doses of 1 mg/kg/week 
or above produced the required efalizumab plasma concen-
trations of 5 μg/mL for binding site down-regulation and 
saturation. No additional clinical beneﬁ  ts of higher doses (eg, 
doses of 2 mg/kg/week and 4 mg/kg/week) were observed 
(Gottlieb et al 2002).
In addition to reduced CD11a expression on the sur-
face of CD3+ T-cells, binding of efalizumab also causes 
a reduced expression of other adhesion molecules, such as 
CD11b, L-selectin or ß7-integrin. The down-modulation 
of these adhesion molecules likely contributes to the anti-
adhesive effects of efalizumab. There is also a decrease of 
αß + T-cell receptors and of TCR-associated co-receptors, Biologics: Targets & Therapy 2007:1(3) 305
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such as CD4, CD8 or CD2. Inhibition of TCR-mediated 
activation therefore seems to also play a role in efalizumab 
mode of action.
Pharmacokinetics
The pharmacokinetic properties of subcutaneous efalizumab 
were determined in an open, multicenter, phase I study of 
70 patients suffering from moderate-to-severe plaque psoria-
sis. Patients received weekly doses of either 1 mg/kg (n = 33) 
or 2 mg/kg (n = 37) efalizumab for 12 weeks subcutaneously 
(Mortensen et al 2005).
After subcutaneous administration of efalizumab, 
peak plasma concentrations are reached after 2–3 days. 
The average estimated bioavailability was about 50% at 
the recommended dose level of subcutaneous efalizumab, 
1.0 mg/kg/week.
Steady-state serum concentrations of efalizumab were 
achieved after 4 doses of weekly efalizumab, 1 mg/kg, and 
after 8 weeks in patients receiving 2 mg/kg. At this dose level 
(with an initial dose of 0.7 mg/kg in the ﬁ  rst week), the mean 
efalizumab plasma trough values were 9.1 ± 6.7 μg/mL in the 
1 mg/kg group and 23.5 ± 12.2 μg/mL in the 2 mg/kg group. 
The volume of distribution of the central compartment after 
single intravenous doses was 110 mL/kg at dose 0.03 mg/kg 
and 58 ml/kg at dose 10 mg/kg.
The metabolism of efalizumab is through internalization 
followed by intracellular degradation as a consequence of 
either binding to cell surface CD11a or through endocyto-
sis. The expected degradation products are small peptides 
and individual amino acids which are eliminated by glo-
merular ﬁ  ltration. Cytochrome P450 enzymes, as well as 
conjugation reactions, are not involved in the metabolism 
of efalizumab.
Efalizumab is cleared by dose-dependent nonlinear 
saturable elimination (Gottlieb et al 2000). Mean steady-
state clearance is 24.3 ± 18.5 and 15.7 ± 12.6 mL/kg/day for 
the 1 mg/kg/week and 2 mg/kg/week groups, respectively. 
The elimination half-life was about 6.21 ± 3.11 days for the 
1 mg/kg/week group and 7.4 ± 2.5 days in the 2 mg/kg/week 
group. Tend at steady-state is 25.5 ± 1.6 days at 1 mg/kg/week 
and 44 ± 10 days at 2 mg/kg/week.
Efalizumab shows dose-dependent nonlinear pharma-
cokinetics which can be explained by its saturable speciﬁ  c 
binding to cell surface receptors CD11a. Clearance was 
more rapid at lower doses, suggesting a receptor-mediated 
mechanism at drug levels below 10 μg/mL.
In a population pharmacokinetic analysis of 1088 
patients, body weight was found to be the most signiﬁ  cant 
covariate affecting efalizumab clearance. Other covariates 
such as baseline PASI, baseline lymphocyte count and age 
had modest effects on clearance; gender and ethnic origin 
had no effect.
Additional pharmacokinetic data are available from an 
open-label extended treatment trial in which patients who 
responded to an initial treatment of efalizumab, 2 mg/kg, for 
12 weeks, received the drug in a maintenance phase for up to 
33 months at a dose of 1 mg/kg. Pharmacokinetic analysis of 
each 12-week treatment period for up to 15 months showed 
that steady-state trough levels remained constant during 
continuous efalizumab dosing. There was no evidence of 
efalizumab accumulation or alteration of the pharmacokinetic 
proﬁ  le of efalizumab during long-term continuous dosing.
Efﬁ  cacy
The efﬁ  cacy of efalizumab for the treatment of adults with 
moderate to severe psoriasis (Table 1) was evaluated in 3 
large phase III studies (Gordon et al 2003; Lebwohl et al 
2003; Leonardi et al 2005). Of these studies, 2 also had 
extension phases lasting an additional 12 weeks (Leonardi 
et al 2005; Menter et al 2005). In addition, an open-label 
study investigating the long-term efﬁ  cacy was initiated 
(Gottlieb et al 2004). The phase III study by Lebwohl and 
colleagues (Lebwohl et al 2003) was divided into three 
phases: a treatment phase from weeks 0 to 12, an extended 
treatment phase from weeks 13 to 24, and lastly a follow-up 
phase from weeks 25 to 36. Two of these studies, one by 
Lebwohl et al (2003), the other by Leonardi and colleagues 
(2005), subjects received efalizumab 1 or 2 mg/kg or placebo 
subcutaneously, after a ﬁ  rst dose of 0.7 mg/kg to reduce 
ﬁ  rst dose adverse events. In the other phase III study by 
Gordon et al (2003), subjects received efalizumab 1.0 mg/kg 
subcutaneously or placebo. In the 3-year long-term study, 
patients were randomized to receive 12 weeks of open-label 
efalizumab 2.0 mg/kg once weekly with or without topical 
ﬂ  uocinolone ointment (0.025%) during weeks 9 through 12. 
After these 12 weeks, patients with a PASI score reduction of 
50% (PASI-50) were then scheduled to receive efalizumab 
1.0 mg/kg once weekly for up to 33 months. Patients that 
relapsed during the maintenance phase were switched to 
once-weekly dosing of 2.0 mg/kg for 12 weeks or 4.0 mg/kg 
for 4 weeks. In the extension study by Menter et al (2006), 
all the patients that ﬁ  nished the initial 12-week double-blind 
phase received efalizumab 1.0 mg/kg/week for a further 
12 weeks. Another extension phase by Leonardi et al (2005), 
patients who received efalizumab previously with PASI score 
reductions less than 75% were then re-randomized to receive Biologics: Targets & Therapy 2007:1(3) 306
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placebo or continue on their previously administered dose 
of efalizumab at 1.0 or 2.0 mg/kg/week.
All of the phase III, double-blind studies used PASI score 
reductions of 75% (PASI-75) after 12 weeks of treatment 
as the primary efﬁ  cacy endpoint. In the long-term study by 
Gottlieb et al (2006), in addition to PASI-75, PASI-50 and 
PASI-90 scores were examined.
The study by Gordon and colleagues (2003) found that 
all efalizumab-treated patients experienced statistically sig-
niﬁ  cant improvement on all end points than those patients 
receiving placebo. Twenty-seven percent of patients receiv-
ing efalizumab achieved PASI-75 versus 4% of the placebo 
group. In addition, 95% of efalizumab-treated patients 
achieved PASI-50 compared with 14% of those receiving 
placebo. With regard to patient reported outcomes, at week 
12, patients treated with efalizumab had a greater mean 
percentage improvement in DLQI with 47% compared with 
14% in the placebo group. Efalizumab treatment also pro-
duced a 38% improvement in Itching Visual Analog Score 
(VAS) compared with placebo. Lastly, efalizumab-treated 
patients had statistically signiﬁ  cant improvement in Psoriasis 
Symptom Assessment (PSA), both frequency and severity 
subscales (48% vs 18% and 46% vs 17%, respectively), 
compared with placebo.
In the extension study published by Menter and col-
leagues (Menter et al 2005), of the 342 subjects who received 
and completed the 12-week course of efalizumab treatment, 
342 enter an open-label treatment period for an additional 
12 weeks, receiving 1 mg/kg/week. In addition, 174 subjects 
who completed a 12-week course of placebo were schedules 
to receive 12 weeks of efalizumab at the same dose. As the 
duration of treatment continued, PASI indexes continued to 
improve. At week 24, 66.6% of the previously efalizumab-
treated patients achieved a PASI-50 response, and 43.8% 
achieved a PASI-75 response. The percentage of patients who 
achieved a static Physician’s Global Assessment (sPGA) of 
minimal or clear increased from 25.7% to 35.9% from week 
12 to 24. For those subjects who received placebo followed 
by efalizumab, 28.7% achieved a sPGA rating of minimal 
or clear after 12 weeks. In addition to physician-assessed 
parameters, there was a statistically signiﬁ  cant improvement 
after 12 weeks of efalizumab treatment in DLQI, Itching 
scale, and PSA frequency and severity.
In a study by Lebwohl and colleagues (2003), patients 
receiving 1 mg/kg/week of efalizumab achieved PASI-75 in 
22% of the subjects and in 28% of those subjects receiving 
2 mg/kg/week, compared with 5% of those subjects receiv-
ing placebo. In the extended treatment phase, those subjects 
achieving PASI-75 or PASI-50 were randomly assigned to 
continue receiving 2 mg/kg of efalizumab weekly or every 
other week or placebo. Those subjects not attaining at least 
PASI-50 were randomly assigned to either an increased 
dose of 4 mg/kg of efalizumab weekly or placebo. It was 
found in the extended treatment phase that the efalizumab-
treated subjects who initially achieved a PASI-75, a greater 
proportion of the subjects who received further treatment 
with efalizumab maintained a PASI-75 compared with those 
receiving placebo (p  0.001). Of those subjects who did 
Table 1 Efﬁ  cacy of efalizumab in the treatment of psoriasis (adapted from Boehncke et al 2006b)
Study  Agent  Study type  No. of   Dosing  Results  Comments
     patients
Gordon 2003  efalizumab  RDBPC  556  1 mg/kg   PASI75 after  
        weekly sc  12 weeks: 27% 
Gottlieb 2006  efalizumab  Open-label  339  2 mg/kg   PASI75 after   Maintenance
       weekly  sc  9–12  weeks:  ∼40% study
       with/without     
       topical  steroid   
Lebwohl 2003  efalizumab  RDBPC  597  1 vs 2 mg/kg   PASI75 after  
        weekly sc  12 weeks:  
          22% vs 28% 
Leonardi 2005  efalizumab  RDBPC  498  1 vs 2 mg/kg   PASI75 after  
        weekly sc  12 weeks:  
          39% vs 27% 
Menter 2005  efalizumab  RDBPC  556  1 mg/kg   PASI75 after  
        weekly sc  12 weeks: 27% 
Papp 2001  efalizumab  RDBPC  145  0.1 vs 0.3 mg/kg  PASI after  Dose-ﬁ  nding
        weekly iv  56 days:   study
          5% vs 25%
Abbreviations: RDBPC, randomized, double-blind, placebo-controlled; iv, intravenous; sc, subcutaneous.Biologics: Targets & Therapy 2007:1(3) 307
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not achieve a PASI-50 on initial efalizumab treatment, an 
improvement of 75% or more was achieved in 40% of those 
subjects receiving efalizumab 4 mg/kg/week, compared with 
15% in the placebo group (p = 0.02).
At the 36-week follow-up, 12 weeks after the discontinu-
ation of study treatment, it was found that in subjects who 
received at least 50% improvement in their PASI index at 
week 24, the time to relapse (loss of at least 50% of the 
improvement in the PASI index that had been achieved 
between base line and week 24) was approximately 
84 days.
Leonardi and colleagues (2005) assessed short-term and 
extended-treatment efﬁ  cacy and safety of efalizumab in 
another phase III study. The study was divided into 3 12-week 
treatment periods, the ﬁ  rst from weeks 1 to 12, and retreat-
ment or extended treatment periods during weeks 13 to 24, 
with 2 observation periods, with subjects receiving an initial 
treatment of efalizumab 1 mg/kg/week, 2 mg/kg/week, or pla-
cebo. During the ﬁ  rst treatment week after 12 weeks, signiﬁ  -
cantly more patients receiving 1 mg/kg and 2 mg/kg achieved 
a PASI-75 (39% and 27%, respectively) compared with those 
subjects receiving placebo (2%). Those efalizumab-treated 
subjects who did not achieve PASI-75 were re-randomized 
at week 12 to receive efalizumab or placebo for an extended 
12-week period. At week 24, 20.3% of subjects who received 
an additional 12 weeks of efalizumab achieved a PASI-75 
compared with 6.7% of those receiving placebo.
Gottlieb and colleagues assessed long-term, continuous 
therapy with efalizumab in a multicenter, open-label, phase 
III study in patients with moderate to severe chronic plaque 
psoriasis. Results for the ﬁ  rst 27 months of this 36-month con-
tinuous therapy trial are available (Gottlieb et al 2006). These 
data document that once-weekly subcutaneous efalizumab 
maintains sustained efﬁ  cacy without toxicity. Patients were 
randomized to receive 12 weeks open-label subcutaneous 
efalizumab 2.0 mg/kg/week with or without topical ﬂ  uocino-
lone during weeks 9 to 12. After the 12th week, patients were 
then scheduled to receive efalizumab, 1.0 mg/kg/week for up 
to 33 weeks, if they received at least a PASI-50 during the 
ﬁ  rst 12 weeks of treatment. If a patient relapsed, therapy was 
increased to 2.0 mg/kg/week for 12 weeks or 4.0 mg/kg/week 
for 4 weeks. Concomitant topical corticosteroids and UVB 
phototherapy were also permitted. PASI improvement was 
maintained throughout the 27-month period.
Safety
Once-weekly injections of efalizumab, 1 mg/kg, was gener-
ally well tolerated for 12 weeks to 15 months (Gordon et al 
2003; Lebwohl et al 2003; Gottlieb et al 2004; Leonardi et al 
2005; Menter et al 2005). In published clinical trials, 3%–6% 
of subjects withdrew due to adverse events of efalizumab 
compared with 1%–3% in the placebo groups. The most 
common adverse events seen in clinical trials included a 
ﬁ  rst dose complex consisting of headache, nausea, myalgia, 
fever, and chills that typically developed within 2 days after 
the ﬁ  rst two injections (Table 2). After the third dose, these 
reactions diminished, with similar incidence in both efali-
zumab and placebo groups (Gordon et al 2003; Lebwohl et al 
2003; Gottlieb et al 2004; Leonardi et al 2005; Menter et al 
2005). These reactions were typically well managed with 
acetaminophen or nonsteroidal anti-inﬂ  ammatory drugs. 
Serious adverse events were uncommon. In the three 12-week 
studies, 2% of efalizumab-treated patients (1 mg/kg/week) 
had a serious adverse event during treatment. Withdraw from 
the studies due to these adverse events were rare as well, 
with a total of 3.5% of efalizumab (1 mg/kg/week) treated 
patients withdrew from treatment due to adverse events in 
these same studies, whereas 2.1% of placebo-treated patients 
withdrew because of adverse events.
Long-term treatment with efalizumab, examined in the 
study by Gottlieb and colleagues (2006), was not associated 
with an overall increased incidence of adverse events. Those 
events noted were similar in nature to those documented 
in short-term trials. There was no evidence of cumulative 
noted. Two serious adverse events that were determined 
by the investigator to be drug related included arthritis and 
gastrointestinal carcinoma.
In the phase III study by Gordon and colleagues (2003), 
infections were present in 27% of efalizumab-treated patients 
compared with 23% of those receiving placebo. Among these 
subjects, there was no increased susceptibility to any certain 
pathogen appreciated upon analysis. In all three phase III 
studies by Gordon et al (2003), Lebwohl et al (2003), and 
Leonardi et al (2005), no statistically signiﬁ  cant increased 
risk of infection was appreciated in the efalizumab treated 
patients compared with those subjects receiving placebo.
Table 2 Safety of efalizumab
Very common  Flu-like symptoms after ﬁ  rst/second injection
 Leukocytosis,  lymphocytosis
Common Rebound
 Exacerbation
 Arthralgia
Rare Thrombocytopenia
  Transient neurophilic dermatosis
Very rare  Severe infectionsBiologics: Targets & Therapy 2007:1(3) 308
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There were 2 cases of malignancy in one clinical trial 
by Gordon and colleagues (2003), which was determined 
to not be related to efalizumab secondary to the time line 
of drug initiation and identiﬁ  cation of malignancy. Accord-
ing to company generated information, of the 2762 patients 
who received efalizumab for a mean duration of 8 months, 
the incidence of malignancies of any kind was 1.8 per 100 
patient-years with efalizumab and 1.6 per 100 patient-years 
with placebo (Raptiva package insert 2005).
During clinical trials, 19 of 2589 patients experience 
worsening (past baseline) of their psoriasis during or after 
treatment with efalizumab. The worsening involved new 
plaques, as well as different forms of their psoriasis, includ-
ing pustular and erythrodermic psoriasis. Some pateints 
required hospitalization and alternate psoriasis treatments 
were administered (Raptiva package insert 2005). Retrospec-
tive analysis of pooled data from different studies, however, 
show that 14% of patients encounter a so-called rebound 
(worsening of psoriasis to 125% of the initial PASI) after 
abrupt termination of efalizumab treatment (Gordon et al 
2002) (Table 2). The likelihood to encounter a rebound is 
particularly high among patients who did not encounter a 
sufﬁ  ciently profound clinical response, and is seemingly rare 
after good clinical improvement.
Clinical and post-marketing data have included reports 
of arthritis, including new onset as well as recurrent, severe 
arthritis (Table 2). Joint pain was noted during treatment as 
well following discontinuation of efalizumab, and typically 
resolved after discontinuation of efalizumab and without 
other therapies (Raptiva package insert 2005).
Platelet counts at or below 52,000 cells/μL were observed 
in 8 subjects during clinical trials (Table 2). Seven (1 patient 
lost to follow-up) were treated with systemic corticosteroids, 
with resolution. Post-marketing surveillance has reported 
cases of severe thrombocytopenia as well, and physicians 
should monitor platelets count closely. Patients experiencing 
thrombocytopenia while taking efalizumab should discon-
tinue treatment (Raptiva package insert 2005). Hemolytic 
anemia, usually 4–6 once after initiation of therapy, was 
noted, and treatment with efalizumab should be stopped if 
this develops (Raptiva package insert 2005).
Efalizumab: clinical use 
and treatment guidelines
Based on the above-mentioned trials, both the FDA as well 
as the EMEA have approved efalizumab for the treatment 
of moderate-to-severe plaque psoriasis in adult patients. 
Whereas efalizumab can be considered alongside with other 
systemic or phototherapy in the US, the more restrictive 
European label demands that patients must have failed to 
respond to, have a contraindication to, or are intolerant to 
other systemic therapy. Two evidence-based European guide-
lines recommend the use of efalizumab in patients fulﬁ  lling 
the above-mentioned criteria deﬁ  ned by the European label 
(Smith et al 2005; Nast et al 2006). Expert comments on these 
criteria have been recently summarized elsewhere (Boehncke 
et al 2006a): In brief, measures currently used to document 
disease severity include determination of the affected BSA, 
PASI, and the DLQI. In the absence of a precise deﬁ  nition, 
moderate to severe psoriasis is considered to be characterised 
by scores >10 in any of these instruments, but other criteria 
such as involvement of the face or joints may also be used.
According to the above-mentioned guidelines, treatment 
should be initiated with an sc injection of 0.7 mg/kg body 
weight, followed by weekly sc injections of 1 mg/kg body 
weight for 12 weeks. The German guideline suggests con-
sideration of continuation in patients with a good clinical 
response (PASI-50) at that time and monthly monitoring 
of hemoglobin, hematocrit, red/white blood cell and platelet 
counts as well as liver enzymes; this should be accompanied 
by a rigid physical examination to detect potential infec-
tions. In case of insufﬁ  cient efﬁ  cacy, the respective patient 
should be switched to another therapy. To prevent a possible 
rebound, the alternative therapy should either follow efali-
zumab treatment immediately or overlap sufﬁ  ciently long to 
guarantee efﬁ  cacy. Since contraindications to conventional 
therapies may limit alterantive options, a potential rescue 
strategy should be deﬁ  ned for each patient individually.
Conclusion
Efalizumab has reproducibly proven its ability to rapidly and 
effectively control symptoms of moderate-to-severe plaque 
psoriasis in several randomized, double-blind, placebo-
controlled clinical studies. This was associated with sub-
stantial improvement of health-related quality of life. Simple 
self-administration and minimal monitoring requirements 
add to the practicability of efalizumab from the patients´ and 
physicians´ perspectives.
Efalizumab was generally well tolerated, with similar 
rates and types of adverse events in the active and placebo 
groups. Injection site reactions were the most frequently 
seen adverse event, presenting mainly as ﬂ  u-like symptoms 
after the ﬁ  rst and second injections, and could be controlled 
by decreasing the dose or with nonsteroidal antiphlogistics. 
Termination of therapy was observed to cause rebound in 
some 15% of patients with low initial responses, but occurred Biologics: Targets & Therapy 2007:1(3) 309
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less frequently (approximately 1%) in patients with a good 
clinical response and could be prevented by adding other 
therapies. Leukocytosis was observed frequently, but stayed 
within physiologic limits and resolved after termination of 
treatment. Thrombocytopenia was observed occasionally, 
as were single cases of hemolytic anemia; thus, monitoring 
should include platelet counts. Dropout rates were approxi-
mately 10%, but usually were not due to adverse effects. 
The risk for adverse events did not increase throughout a 
15-month observation period.
Two evidence-based European guidelines recommend the 
use of efalizumab in adult patients with moderate-to-severe 
plaque psoriasis.
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